STOCK TITAN
  1. Home
  2. News
  3. EXAS

Exact Sciences Corp. - EXAS STOCK NEWS

Welcome to our dedicated news page for Exact Sciences (Ticker: EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Exact Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Exact Sciences's position in the market.

News
Exact Sciences Announces Fourth Quarter 2023 Results
Rhea-AI Summary
Exact Sciences Corp. reports record revenue, positive free cash flow, and expects 2024 revenue of $2.810-2.850 billion. The fourth quarter and 2023 highlights include total revenue of $647 million, a 17% increase, with Screening revenue at $487 million and Precision Oncology revenue at $160 million. The company's financial results showcase growth in both revenue and cash flow, reflecting a strong performance in cancer screening and diagnostic tests.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6%
Tags
earnings
-
News
Exact Sciences Schedules Fourth Quarter 2023 Earnings Call
Rhea-AI Summary
Exact Sciences Corp. (Nasdaq: EXAS) plans to release its fourth quarter 2023 financial results on February 21, 2024, followed by a webcast and conference call to discuss financial results and business progress. The webcast and call will be open to all interested parties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.25%
Tags
earnings
-
News
Exact Sciences Announces Preliminary Fourth Quarter 2023 Results
Rhea-AI Summary
Exact Sciences Corp. (Nasdaq: EXAS) anticipates record fourth-quarter revenue, expects full-year 2024 revenue of $2.83 billion, and submits next-generation Cologuard to FDA. The company also announces Chief Financial Officer succession plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.59%
Tags
earnings
News
Exact Sciences to participate in J.P. Morgan Healthcare Conference
Rhea-AI Summary
Exact Sciences Corp. (Nasdaq: EXAS) will participate in the J.P. Morgan Healthcare Conference on January 8, 2024, at 2:15 p.m. ET, with a webcast available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
conferences
-
News
Exact Sciences Awards Grants to 23 Organizations Focused on Increasing Colorectal Cancer Screenings
Rhea-AI Summary
Exact Sciences (EXAS) awarded $1.3 million to 23 organizations through its FOCUS Program to improve colorectal cancer screening rates. Since 2022, the program has awarded $2.9 million to 50 organizations. The company developed Cologuard, the first FDA-approved noninvasive screening test, and has delivered over 13 million results since 2014.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
none
-
News
Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients
Rhea-AI Summary
Exact Sciences Corp. (NASDAQ: EXAS) will present new data and study results at the 2023 annual San Antonio Breast Cancer Symposium (SABCS). The data includes updated TAILORx follow-up data, concordance analysis supporting the generation of Oncotype DX results from core needle biopsy, ADAPTcycle trial data, and prospective trial data regarding the potential omission of radiation therapy after surgery in certain patients with ductal carcinoma in situ (DCIS). The company aims to refine distant recurrence risk estimates, personalize treatment decisions, and expand the number of breast cancer patients able to forgo chemotherapy post-surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.73%
Tags
none
News
Exact Sciences Files Patent Infringement Lawsuit Against Geneoscopy
Rhea-AI Summary
Exact Sciences Corp. (Nasdaq: EXAS) has filed a lawsuit against Geneoscopy, Inc. in the United States District Court for the District of Delaware, seeking damages and a court order to stop Geneoscopy from infringing on Exact Sciences' U.S. Patent No. 11,634,781. The patent covers methods for processing fecal samples at home for subsequent analysis in a clinical laboratory, central to Exact Sciences' Cologuard® stool DNA-based colorectal cancer screening test. After a reexamination by the USPTO, Geneoscopy's challenge to the patent was rejected, confirming its patentability for Exact Sciences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.39%
Tags
none
-
News
Exact Sciences Announces Third-Quarter 2023 Results
Rhea-AI Summary
Exact Sciences Corp. reports record revenue of $628 million in the third quarter of 2023, delivering over 1 million test results. Full-year revenue and adjusted EBITDA guidance raised by $28 million and $25 million, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
earnings
-
News
Exact Sciences to participate in November investor conferences
Rhea-AI Summary
Exact Sciences Corp. (Nasdaq: EXAS) announced that company management will participate in several upcoming conferences and invited investors to participate by webcast. The conferences include Stifel Healthcare Conference, Jefferies London Healthcare Conference, Piper Sandler 35th Annual Healthcare Conference, and Evercore ISI HealthCONx Conference. The webcasts can be accessed on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.13%
Tags
conferences
News
Next-Generation Cologuard® Test Demonstrates High Sensitivity and Specificity in Pivotal BLUE-C Study, Significantly Outperforming Fecal Immunochemical Testing (FIT) for Cancer and Precancer Detection
Rhea-AI Summary
Exact Sciences Corp. announces late-breaking data from the BLUE-C trial showing the next-generation Cologuard test met all study endpoints, demonstrating 94% sensitivity for colorectal cancer at 91% specificity. Results show next-generation Cologuard test superior to FIT in sensitivity for colorectal cancer and pre-cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock EXAS logo
Exact Sciences Corp.

Nasdaq:EXAS

EXAS Rankings

#773 Ranked by Market Cap
#234 Ranked by Stock Gains
N/A Ranked by Dividends

EXAS Stock Data

12.95B
179.56M
1.01%
89.38%
3.49%
Diagnostic Imaging Centers
Health Care and Social Assistance
Link
US
Madison

About EXAS

exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences'​ noninvasive colon cancer screening test, visit cologuardtest.com